These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

948 related articles for article (PubMed ID: 31907599)

  • 1. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
    Adams D; Ando Y; Beirão JM; Coelho T; Gertz MA; Gillmore JD; Hawkins PN; Lousada I; Suhr OB; Merlini G
    J Neurol; 2021 Jun; 268(6):2109-2122. PubMed ID: 31907599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
    Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
    Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
    Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
    Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.
    Alcantara M; Mezei MM; Baker SK; Breiner A; Dhawan P; Fiander A; Fine NM; Hahn C; Katzberg HD; Khayambashi S; Massie R; Matte G; Putko B; Siddiqi Z; Delgado D; Bril V
    Can J Neurol Sci; 2022 Jan; 49(1):7-18. PubMed ID: 33631091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
    Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
    Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic.
    Di Stefano V; Lupica A; Alonge P; Pignolo A; Augello SM; Gentile F; Gagliardo A; Giglia F; Brinch D; Cappello M; Di Lisi D; Novo G; Borgione E; Scuderi C; Brighina F
    Eur J Neurol; 2024 Jan; 31(1):e16065. PubMed ID: 37725003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.
    Ando Y; Waddington-Cruz M; Sekijima Y; Koike H; Ueda M; Konishi H; Ishii T; Coelho T
    Orphanet J Rare Dis; 2023 Oct; 18(1):323. PubMed ID: 37828588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
    Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
    Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electro-clinical presentation of hereditary transthyretin related amyloidosis when presenting as a polyneuropathy of unknown origin in northern France.
    Davion JB; Bocquillon P; Cassim F; Frezel N; Lacour A; Dhaenens CM; Maurage CA; Gibier JB; Hachulla E; Nguyen The Tich S; Defebvre L; Merle PE; Tard C
    Rev Neurol (Paris); 2021 Nov; 177(9):1160-1167. PubMed ID: 34253345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.
    Gertz M; Adams D; Ando Y; Beirão JM; Bokhari S; Coelho T; Comenzo RL; Damy T; Dorbala S; Drachman BM; Fontana M; Gillmore JD; Grogan M; Hawkins PN; Lousada I; Kristen AV; Ruberg FL; Suhr OB; Maurer MS; Nativi-Nicolau J; Quarta CC; Rapezzi C; Witteles R; Merlini G
    BMC Fam Pract; 2020 Sep; 21(1):198. PubMed ID: 32967612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
    Kaku MC; Bhadola S; Berk JL; Sanchorawala V; Connors LH; Lau KHV
    Amyloid; 2022 Sep; 29(3):184-189. PubMed ID: 35253562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy.
    Tojo K; Tsuchiya-Suzuki A; Sekijima Y; Morita H; Sumita N; Ikeda S
    Amyloid; 2010 Mar; 17(1):32-5. PubMed ID: 20132088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry.
    Pinto MV; Pinto LF; Dias M; Rosa RS; Mundayat R; Pedrosa RC; Waddington-Cruz M
    J Neurol Sci; 2019 Aug; 403():1-6. PubMed ID: 31163298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.
    Pasutharnchat N; Taychargumpoo C; Vorasettakarnkij Y; Amornvit J
    BMC Neurol; 2021 May; 21(1):206. PubMed ID: 34022837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nerve ultrasonography findings as possible pitfall in differential diagnosis between hereditary transthyretin amyloidosis with polyneuropathy and chronic inflammatory demyelinating polyneuropathy.
    Leonardi L; Vanoli F; Fionda L; Loreti S; Garibaldi M; Morino S; Salvetti M; Russo D; Musumeci B; Antonini G
    Neurol Sci; 2020 Dec; 41(12):3775-3778. PubMed ID: 32936357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.
    Nativi-Nicolau JN; Karam C; Khella S; Maurer MS
    Heart Fail Rev; 2022 May; 27(3):785-793. PubMed ID: 33609196
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 48.